Users Online: 1013 | Home Print this page Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL RESEARCH ARTICLE
Year : 2018  |  Volume : 8  |  Issue : 2  |  Page : 63-68

In vivo evaluation of the aromatase inhibition by 4-((1H-imidazol-1-yl) methyl)-2-(4-fluorophenyl)- 8-phenylquinoline


1 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
2 Biotechnology Research Center, Pharmaceutical Technology Institute; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
3 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
4 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence Address:
Prof. Farzin Hadizadeh
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, P. O. Box: 9196773117, Mashhad
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jphi.JPHI_17_18

Rights and Permissions

Objective: Some of aromatase inhibitors (AIs) are Food and Drug Administration-approved agents which are used as first-line therapy in the treatment of endocrine-responsive breast cancer. In this study, we aimed to develop new quinoline derivative with higher specificity and potency. Materials and Methods: The in vivo aromatase inhibition of these compounds was evaluated by measuring the inhibition of the androstenedione-induced uterine hypertrophy. The selectivity of aromatase inhibition has been investigated by the inhibition of adrenocorticotropic hormone stimulation on the plasma concentrations of aldosterone and cortisol. Results: Letrozole (10 μg/kg) could significantly inhibit uterine hypertrophy in positive control group that received androstenedione 30 mg/kg/day. Furthermore, quinoline derivative could decrease the androstenedione-induced uterine hypertrophy in a dose-dependent manner. Interestingly, there was no significant difference between inhibitory potency of letrozole and quinoline derivatives. High dose of letrozole could significantly decrease the serum concentration of aldosterone and cortisol as compared to control group. On the other hand, the same doses of quinoline derivative were administered; it did not show any significant effects on the serum concentration of either aldosterone or cortisol. Conclusion: This report introduced a new compound that can be considered as new lead for further investigation to explore the more potent and more selective AIs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed384    
    Printed57    
    Emailed0    
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal